Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human

Mariko Miyashita1, Kaori Koga, Masashi Takamura

  • 1Department of Obstetrics and Gynecology, University of Tokyo , Tokyo , Japan.

Insights

Dienogest treatment for endometriosis significantly reduces cell proliferation and aromatase expression while increasing apoptosis in lesion tissues. This study clarifies how dienogest impacts endometriosis at a cellular level.

Area of Science:

  • Reproductive Medicine
  • Pharmacology
  • Cell Biology

Background:

  • Endometriosis is a common gynecological condition.
  • Dienogest is a progestin used to treat endometriosis.
  • The in vivo effects of dienogest on endometriosis tissue are not fully understood.

Purpose of the Study:

  • To evaluate the in vivo effect of dienogest on endometriosis lesion tissues.
  • To investigate histological changes in endometrioma after dienogest administration.

Main Methods:

  • Collected endometrioma tissues from patients treated with dienogest (N=7) and controls (N=11).
  • Assessed cell proliferation (Ki67), aromatase expression, blood vessel density (von Willebrand factor), and apoptosis (TUNEL assay).

Main Results:

  • Dienogest treatment significantly reduced Ki67 and aromatase-positive epithelial cells (p<0.05).
  • Apoptosis (TUNEL-positive cells) was significantly increased in the dienogest group (p<0.05).
  • Blood vessel density showed a marginal decrease in the dienogest group (p=0.20).

Conclusions:

  • Dienogest treatment leads to reduced proliferation, aromatase expression, and angiogenesis in endometriosis tissues.
  • Increased apoptosis is observed in endometrioma tissues from patients treated with dienogest.
  • These histological changes explain the therapeutic efficacy of dienogest in endometriosis.

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
58.4K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.4K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
5.1K